Clearmind completes recruitment for CMND-100 segment

Part B is designed to assess safety, tolerability, pharmacokinetics and early efficacy signals, including potential reductions in alcohol craving.

Rhea-AI Filing Summary

Clearmind Medicine Inc. (CMND) completed patient recruitment for the first segment of Part B of its CMND-100 Phase I/IIa trial in patients with moderate-to-severe Alcohol Use Disorder. Part B is the company’s first clinical evaluation of CMND-100 in patients diagnosed with the disorder, following Part A in healthy volunteers.

Part B consists of two sequential single-dose ascending cohorts, at 80 mg and 160 mg, with six patients per cohort. The trial is designed to assess safety, tolerability, pharmacokinetics and early efficacy signals, including potential reductions in alcohol craving. Sites include Johns Hopkins University School of Medicine and Yale School of Medicine in the United States, and Tel Aviv Sourasky Medical Center and Hadassah Medical Center in Israel.

Filing Explained

The filing incorporates the first three paragraphs of Clearmind’s October 27 press release into its listed Form F-3 and Form S-8 registration statements from the filing date, unless later reports supersede them.

Key Figures

Part B dose cohorts: 2 cohorts First dose cohort: 80 mg Second dose cohort: 160 mg +1 more

4 metrics

Part B dose cohorts 2 cohorts Sequential single-dose ascending cohorts

First dose cohort 80 mg Part B

Second dose cohort 160 mg Part B

Patients per cohort 6 patients Part B

Key Terms

Phase I/IIa clinical trial, single-dose ascending cohorts, pharmacokinetics, neuroplastogens

4 terms

Phase I/IIa clinical trial medical

"CMND-100 Phase I/IIa clinical trial"

An early-stage clinical study that combines initial safety testing (Phase I) with a first look at whether a treatment shows signs of working in patients (Phase IIa). Investors watch these trials because they move a therapy from lab research toward proof that it can help people; successful results reduce technical risk and can unlock bigger trials, partnerships, regulatory attention, or increases in a company’s value — like a prototype test that determines whether a product should go into full production.

single-dose ascending cohorts medical

"two sequential single-dose ascending cohorts"

pharmacokinetics medical

"safety, tolerability, pharmacokinetics"

Pharmacokinetics is the study of how a substance, such as a drug or chemical, moves through and is processed by the body over time. It tracks how it is absorbed, distributed, broken down, and eventually eliminated. For investors, understanding pharmacokinetics helps gauge the effectiveness, safety, and potential risks of new medications or treatments, which can influence a company’s success and valuation in the healthcare industry.

neuroplastogens technical

"non-hallucinogenic psychedelic-derived neuroplastogens"

Neuroplastogens are drugs or molecules designed to boost the brain’s ability to reorganize and form new connections—think of them as medicines that help the brain ‘rewire’ itself after damage or during therapy. Investors watch them because successful neuroplastogens could become treatments for conditions like depression, Alzheimer’s, or brain injury, creating large markets and sharp changes in company value as trials, approvals, or setbacks occur.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many patients are in each CMND-100 Part B cohort?

Each of the two sequential single-dose ascending cohorts consists of six patients; the dose levels are 80 mg and 160 mg.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 6-K: How Foreign Companies Report to the SEC →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 10/27/2026 - 08:24 AM EDT Accepted by SEC EDGAR 10/27/2026 - 08:24 AM EDT Learn about SEC filing dates

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 6-K

Report of Foreign Private Issuer

Pursuant to Rule 13a-16 or 15d-16

under the Securities Exchange Act of 1934

For the month of: October 2026

Commission file number: 001-41557

CLEARMIND MEDICINE INC.

(Translation of registrant’s name into English)

101 – 1220 West 6th Avenue

Vancouver, British Columbia

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☒    Form 40-F ☐

CONTENTS

Attached hereto and incorporated herein is the Registrant’s press release issued on October 27, 2026, titled “Clearmind Successfully Completes Patient Recruitment for the First Alcohol Use Disorder Cohort of its CMND-100 Phase I/IIa Clinical Trial.”

The first three paragraphs of the press release attached to this Form 6-K as Exhibit 99.1 are incorporated by reference into the Registrant’s Registration Statements on Form F-3 (File Nos. 333-275991, 333-270859, 333-273293, 333-290404, 333-293521 and 333-295455) and Form S-8 (File No. 333-283695), filed with the Securities and Exchange Commission, to be a part thereof from the date on which this report is submitted, to the extent not superseded by documents or reports subsequently filed or furnished.

1

EXHIBIT INDEX

Exhibit No.
99.1		Press release titled: “Clearmind Successfully Completes Patient Recruitment for the First Alcohol Use Disorder Cohort of its CMND-100 Phase I/IIa Clinical Trial”

2

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	Clearmind Medicine, Inc.
	(Registrant)
Date: October 27, 2026	By:	/s/ Adi Zuloff-Shani
	Name:	Adi Zuloff-Shani
	Title:	Chief Executive Officer

3

Exhibit 99.1

Clearmind Successfully Completes Patient Recruitment for the First Alcohol Use Disorder Cohort of its CMND-100 Phase I/IIa Clinical Trial

Milestone advances Clearmind’s clinical program as the company continues to develop CMND-100 as a potential novel therapeutic candidate for alcohol use disorder

Vancouver, Canada, Oct. 27, 2026 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND) (“Clearmind” or the “Company”), a clinical-stage biopharmaceutical company advancing non-hallucinogenic psychedelic-derived neuroplastogens for scalable treatment of neuropsychiatric, metabolic, and addiction disorders including Alcohol Use Disorder (“AUD”), today announced the completion of patient recruitment for the first segment of Part B of its ongoing Phase I/IIa clinical trial evaluating CMND-100 in patients with moderate-to-severe Alcohol Use Disorder (AUD).

Part B marks Clearmind’s first clinical evaluation of CMND-100 in patients diagnosed with AUD, following the successful completion of Part A in healthy volunteers. Part B consists of two sequential single-dose ascending cohorts (80 mg and 160 mg), each consisting of six patients, designed to assess safety, tolerability, pharmacokinetics, and early signals of clinical efficacy, including potential reductions in alcohol craving.

The trial is being conducted at leading clinical sites in the United States and Israel, including Johns Hopkins University School of Medicine, Yale School of Medicine, Tel Aviv Sourasky Medical Center, and Hadassah Medical Center.

“Completing recruitment for the first portion of Part B marks a significant advancement for our CMND-100 clinical program, as we transition from healthy volunteers to the very patient population we aim to impact,” said Dr. Adi Zuloff-Shani, Chief Executive Officer of Clearmind Medicine. “Building on the safety and tolerability data observed in Part A and the continued support of our clinical partners, we are now positioned to generate the first dedicated clinical dataset evaluating CMND-100 in individuals with AUD- a major milestone toward validating its therapeutic potential in a large and underserved market.”

About Clearmind Medicine Inc.

Clearmind is a clinical-stage neuroplastogens pharmaceutical biotech company focused on the discovery and development of non-hallucinogenic, second generation, neuroplastogen-derived therapeutics to solve widespread and underserved health problems, including alcohol use disorder. Its primary objective is to research and develop psychedelic-based compounds and attempt to commercialize them as regulated medicines, foods, or supplements.

The Company’s intellectual property portfolio currently consists of nineteen patent families, including 32 granted patents. The Company intends to seek additional patents for its compounds whenever warranted and will remain opportunistic regarding the acquisition of additional intellectual property to build its portfolio.

Shares of Clearmind are listed for trading on Nasdaq under the symbol “CMND.”

For further information, visit: https://www.clearmindmedicine.com or contact:

Investor Relations
invest@clearmindmedicine.com
www.Clearmindmedicine.com

Forward-Looking Statements:

This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act and other securities laws. Words such as “expects,” “anticipates,” “intends,” “plans,” “believes,” “seeks,” “estimates” and similar expressions or variations of such words are intended to identify forward-looking statements. For example, the continued clinical development of CMND-100; the potential for Part B of the Phase I/IIa clinical trial to generate data regarding CMND-100’s safety, tolerability, pharmacokinetics and clinical efficacy, including potential reductions in alcohol craving; and the potential therapeutic benefits of CMND-100 for individuals with AUD. Forward-looking statements are not historical facts, and are based upon management’s current expectations, beliefs and projections, many of which, by their nature, are inherently uncertain. Such expectations, beliefs and projections are expressed in good faith. However, there can be no assurance that management’s expectations, beliefs and projections will be achieved, and actual results may differ materially from what is expressed in or indicated by the forward-looking statements. Forward-looking statements are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in the forward-looking statements. For a more detailed description of the risks and uncertainties affecting the Company, reference is made to the Company’s reports filed from time to time with the Securities and Exchange Commission (“SEC”), including, but not limited to, the risks detailed in the Company’s annual report on Form 20-F for the fiscal year ended October 31, 2025 and subsequent filings with the SEC. Forward-looking statements speak only as of the date the statements are made. The Company assumes no obligation to update forward-looking statements to reflect actual results, subsequent events or circumstances, changes in assumptions or changes in other factors affecting forward-looking information except to the extent required by applicable securities laws. If the Company does update one or more forward-looking statements, no inference should be drawn that the Company will make additional updates with respect thereto or with respect to other forward-looking statements. References and links to websites have been provided as a convenience, and the information contained on such websites is not incorporated by reference into this press release. Clearmind is not responsible for the contents of third-party websites.

Filing Exhibits & Attachments

1 document

Press Releases

• EX-99.1 PRESS RELEASE TITLED: "CLEARMIND SUCCESSFULLY COMPLETES PATIENT RECRUITMENT FOR 9.2 KB